Results 61 to 70 of about 999,769 (295)

Pulmonary rehabilitation in idiopathic pulmonary fibrosis and COPD: a propensity matched real-world study [PDF]

open access: yes, 2021
BACKGROUND: The adherence to and clinical efficacy of pulmonary rehabilitation in idiopathic pulmonary fibrosis (IPF), particularly in comparison to people with chronic obstructive pulmonary disease (COPD), remains uncertain.
Ingram, Karen A   +21 more
core   +1 more source

High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis

open access: yesBMC Cancer, 2022
Background Idiopathic pulmonary fibrosis (IPF) is the most common type of interstitial pneumonia. Lung cancer, mainly non-small cell lung cancer (NSCLC), is a complication of idiopathic pulmonary fibrosis.
Wenxin Kou   +7 more
doaj   +1 more source

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond

open access: yesCardiac failure review, 2022
Pirfenidone (PFD) slows the progression of idiopathic pulmonary fibrosis (IPF) by inhibiting the exaggerated fibrotic response and possibly through additional mechanisms, such as anti-inflammatory effects.
A. Aimo   +10 more
semanticscholar   +1 more source

Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset [PDF]

open access: yes, 2011
Acute periods of pulmonary exacerbation are the single most important cause of morbidity in cystic fibrosis patients, and may be associated with a loss of lung function.
Matt W Johnson   +19 more
core   +1 more source

Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy

open access: yesNature Communications
Lipid nanoparticle-assisted mRNA inhalation therapy necessitates addressing challenges such as resistance to shear force damage, mucus penetration, cellular internalization, rapid lysosomal escape, and target protein expression.
Xin Bai   +7 more
semanticscholar   +1 more source

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis

open access: yesBMC Pulmonary Medicine, 2021
Background Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of anti-fibrotic therapy (grouping nintedanib and pirfenidone together) in patients with ...
J. Finnerty   +4 more
semanticscholar   +1 more source

Differences in Response to Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease. [PDF]

open access: yes, 2010
Background: The benefits of pulmonary rehabilitation in chronic obstructive pulmonary disease (COPD) are well recognized. However, whether individuals with idiopathic pulmonary fibrosis (IPF) benefit is less clear.
Senjyu, H.   +17 more
core   +1 more source

Extending Service Beyond Active Duty: Generalizability of Rheumatoid Arthritis Research Conducted Among U.S. Veterans

open access: yesArthritis Care &Research, Accepted Article.
Biomedical research involving United States Veterans continues to advance healthcare beyond the Veterans Health Administration. This is particularly true in rheumatoid arthritis (RA), where Veteran‐centric research has uncovered novel insights into pathogenesis, risk factors, and disease manifestations, informing clinical care and research across both ...
Austin M. Wheeler   +20 more
wiley   +1 more source

Impact of renal function on survival in idiopathic pulmonary fibrosis patients 65 years and older undergoing lung transplantation in the United StatesCentral MessagePerspective

open access: yesJTCVS Open
Objective: Changes in patient demographics, pharmacotherapies, and allocation systems have increased the number of patients receiving a lung transplant at an older age.
Koray N. Potel, MB, BCh, BAO   +7 more
doaj   +1 more source

A Holistic Platform Approach for Developing Robust Pulmonary mRNA Delivery: Integrating Novel Phenolic Acid‐Derived Ionizable Lipids and Device Engineering

open access: yesAdvanced Functional Materials, EarlyView.
An integrated pulmonary mRNA delivery platform combining novel biodegradable syringic acid‐derived ionizable lipids, design‐of‐experiments formulation optimization, and vibrating‐mesh nebulizer engineering enabled stable aerosolization and efficient lung delivery.
Neha Kaushal   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy